A comparison of intralesional verapamil and triamcinolone monotherapy in the treatment of keloids in an African population

Belie, Orimisan; Ugburo, Andrew Omotayo; Mofikoya, Bolaji O; Omidiji, Olubukola; Belie, M F

doi:10.4103/njcp.njcp_474_20

Cited by 10 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One previous study held in 2020 at Nigeria compared the efficacy and side effects among patients given treatment for keloids. They concluded that complete resolution of symptoms happened in group receiving Triamcinolone over 6-8 weeks of treatment 13 . Our results were in line with above mentioned study that showed 3.3% recurrence in patients receiving Triamcinolone.…”

Section: Discussionmentioning

confidence: 98%

Comparison of Intra-lesional Verapamil and Intra-lesional Triamcinolone Acetonide in Treatment of Keloid

Anjum,

Hassan,

Shahzad

et al. 2023

PJMHS

View full text Add to dashboard Cite

Background: Keloid is a fibrous tissue that extends past the edges of an incision. Intralesional triamcinolone acetonide is the corticosteroid most frequently used to treat keloids. Aim: To contrast the effects of intralesional triamcinolone acetonide and intralesional verapamil in treating keloid among dermatology department patients. Study Design: Comparative clinical study. Methodology: The current study was carried out at dermatology department with enrollment of 60 individuals each in both groups. Using a 30 gauge needle connected to an insulin syringe, both groups underwent intra-lesional injections in keloids three weeks apart for a total of six sessions. After the treatment was over for three months, a follow-up was conducted. SPSS 23 was used for the data analysis. Chi-square/exact Fisher's tests with a p-value of less than 0.05 were used to compare the gender distribution, outcomes, responder, and recurrence rate between the two groups. Results: Patients in group A had a mean age of 28.1 +/- 5.4 years, while those in group B had a mean age of 29.3 +/- 4.7 years. There was insignificant difference in terms of remission between both groups with 53 (88.3%) of patients in group A and 58 (96.7%) of patients in group B. However, recurrence was seen in 2 (3.3%) of the patients in group B, compared to 6 (10%) of the patients in group A, with an insignificant p-value (0.272). Practical Implication: Due to its affordability and safety, this study aided researchers in examining the effectiveness of intra-lesional verapamil as a treatment for keloid removal. Second, it contributed to the body of knowledge in the area regarding other comparable and successful treatment choices. Conclusion: It was concluded that there was insignificant difference among both groups with respect to outcomes having p-value greater than 0.05. Key words: Keloid, Intralesional Verapamil, Triamcinolone Acetonide and Clinical Outcomes.

show abstract

Section: Discussionmentioning

confidence: 98%

Comparison of Intra-lesional Verapamil and Intra-lesional Triamcinolone Acetonide in Treatment of Keloid

Anjum,

Hassan,

Shahzad

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

“…A study by Belie et al, however, showed the success of intralesional TAC over verapamil, a calcium channel blocker, in reducing keloid-associated pain and pruritus in a sample of African patients. 27 While after 6 weeks both groups demonstrated statistically significant reductions in keloid height, TAC more quickly and completely reduced patient-reported symptoms. 27 Although 80% of patients in the TAC group had hypopigmentation and skin atrophy, these side effects were localized to the affected site, whereas patients in the verapamil group suffered from systemic side effects.…”

Section: Corticosteroidsmentioning

confidence: 89%

A Comprehensive Review of Non-Surgical Treatments for Hypertrophic and Keloid Scars in Skin of Color

Bronte,

Zhou,

Vempati

et al. 2024

CCID

View full text Add to dashboard Cite

“…Therapeutic efficacy was reported in 18 studies. [13][14][15][16][22][23][24][25][26][27][28][29][30][31][32][33][34][35] A total of 6 interventions were evaluated: 1 combination therapy comprising TAC and 5-FU and 5 monotherapies involving TAC, 5-FU, BTA, verapamil, or bleomycin. The network plot of therapeutic efficacy is depicted in Figure 2.…”

Section: Therapeutic Efficacymentioning

confidence: 99%

“…11 Clinical trials have been conducted to evaluate the efficacy of drugs other than TAC, such as 5-fluorouracil (5-FU), botulinum toxin A (BTA), bleomycin, and verapamil, in the treatment of keloids. [13][14][15][16] However, few studies have been conducted to compare these drugs in terms of efficacy. Therefore, in this study, we performed a network meta-analysis to evaluate the safety and efficacy of several drugs used in the intralesional injection therapy for keloids.…”

mentioning

confidence: 99%

Comparative Efficacy of Drug Interventions for Keloids

Yang,

Jheng,

et al. 2024

Ann Plast Surg

View full text Add to dashboard Cite

Background Keloids are common benign skin lesions originating from a disorganized fibroproliferative collagen response; these lesions often lead to both physical and psychological problems. The optimal treatment for keloids is yet to be standardized. Intralesional injection, which is simple and nontraumatic, is one of the most commonly used treatment modalities for these lesions. In this study, we compared 5 different drugs (intralesional injections) for the treatment of keloids in terms of efficacy. Methods We systemically searched relevant studies on PubMed, EMBASE, and Cochrane Library. Randomized clinical trials on the safety and efficacy of triamcinolone acetonide (TAC), 5-fluorouracil (5-FU), botulinum toxin A (BTA), verapamil, and bleomycin were included in this study. Results This network meta-analysis included a total of 1114 patients from 20 randomized controlled trials. Botulinum toxin A alone and TAC plus 5-FU exhibited significantly better efficacy than did 5-FU, TAC, and verapamil. No significant difference in efficacy between BTA alone and TAC combined with 5-FU was observed. No significant differences were noted in the adverse event rate between BTA, TAC plus 5-FU, 5-FU, and TAC. Furthermore, we performed surface under the cumulative ranking curve analyses to predict the rank of each intervention (by efficacy and adverse event rate). The predicted ranking by efficacy was as follows: TAC plus 5-FU, BTA, bleomycin, TAC, 5-FU, and verapamil; the predicted ranking by adverse events was as follows: TAC, 5-FU, TAC plus 5-FU, and BTA. Funnel plot analysis revealed no publication bias. Conclusions Botulinum toxin A and TAC plus 5-FU appear to have outstanding therapeutic efficacy for keloids. The rate of adverse events was similar among BTA, TAC, 5-FU, and TAC plus 5-FU. Nonetheless, additional reviews of rigorous, large-scale randomized controlled trials are warranted for further validation of our findings.

show abstract

A comparison of intralesional verapamil and triamcinolone monotherapy in the treatment of keloids in an African population

Cited by 10 publications

References 0 publications

Comparison of Intra-lesional Verapamil and Intra-lesional Triamcinolone Acetonide in Treatment of Keloid

Comparison of Intra-lesional Verapamil and Intra-lesional Triamcinolone Acetonide in Treatment of Keloid

A Comprehensive Review of Non-Surgical Treatments for Hypertrophic and Keloid Scars in Skin of Color

Comparative Efficacy of Drug Interventions for Keloids

Contact Info

Product

Resources

About